期刊文献+

我院质子泵抑制剂不合理用药分析 被引量:10

Analysis of Irrational Use of Proton Pump Inhibitors in Our Hospital
原文传递
导出
摘要 目的对我院质子泵抑制剂(PPIs)进行合理用药专项点评并针对结果进行分析,为PPIs临床合理应用提供参考。方法随机抽取我院2018年12月26日~2019年5月25日的门诊处方1000张及出院病历564份,对处方及医嘱用药适宜性进行合理用药评价并进行分析。结果总体不合理用药率为6.7%(门诊和住院分别5.0%与9.8%);PPIs不合用药类型分布:用药指征不适宜占25.7%(28例)、用法用量不适宜占42.2%(46例)、剂型选择不当占12.8%(14例)、疗程过长占9.2%(10例)、联用不当占6.4%(7例)、重复用药占3.7%(4例)。结论我院PPIs的合理使用仍需进一步加强,尤其应严格把握PPIs的预防使用指征、预防使用剂量以及剂型的选择。 OBJECTIVE To evaluate and analyze the rational drug use of proton pump inhibitors(PPIs) in the hospital so as to provide the reference for the clinician. METHODS 1 000 outpatient prescriptions and 564 discharged medical records were randomly sampled from December 26, 2018 to May 25, 2019.The suitability of prescriptions for PPIs use was evaluated and analyzed. RESULTS The overall unreasonable PPIs use rate was 6.7%(5.0% in outpatient and 9.8% in hospital, respectively);Distribution of unsuitable drug use problems:unsuitable indications of medication accounted for 25.7%(28 cases), unsuitable usage and dosage accounted for 42.2%(46 cases), improper dosage form selection accounted for 12.8%(14 cases), excessive course of treatment accounted for 9.2%(10 cases), improper combination accounted for 6.4%(7 cases) and repeated use accounted for 3.7%(4 cases). CONCLUSION The rational use of PPIs should be further strengthened, expecially in the indication, dosage and dosage form.
作者 刘霭明 罗蓓 LIU Aiming;LUO Bei(Department of Pharmacy,Shunde Hospital of Southern Medical University,FoShan,Guangdong 528000,China)
出处 《今日药学》 CAS 2019年第12期828-831,共4页 Pharmacy Today
关键词 质子泵抑制剂 合理用药 处方点评 proton pump inhibitors rational drug use prescription comment
  • 相关文献

参考文献6

二级参考文献49

  • 1Soumana C Nasser,Jeanette G Nassif,Hani I Dimassi.Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients[J].World Journal of Gastroenterology,2010,16(8):982-986. 被引量:23
  • 2李兆申.重视应激性溃疡的规范化防治[J].世界华人消化杂志,2005,13(22):2637-2639. 被引量:88
  • 3Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient [J]. Nat Rev Gastroenterol Hepatol, 2015, 12(2): 98-107.
  • 4Choung RS, Talley NJ. Epidemiology and clinical presentation of stress-related peptic damage and ehronic peptic ulcer [J]. Curt Mol M~d, 2008, 8(4): 253-257.
  • 5Krag M, Perner A, Wetterslev J, et al. Stress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic re- view[J]. Acta Anaesthesiol Scand, 2013, 57(7): 835-847.
  • 6Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastroin- testinal bleeding in critically ill patients. Canadian Critical Care Trials Group[J]. N Engl J Med, 1994, 330(6): 377-381.
  • 7Cook D J, Griffith LE, Walter SD, et al. The attributable mortali- ty and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients [J]. Crit Care, 2001, 5(6): 368-375.
  • 8Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside [J]. Gastroenterology, 2008,135 ( 1):41-60.
  • 9Fennerty MB.Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression [J]. Crit Care Med, 2002, 30 (suppl): 351-355.
  • 10MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit[J]. JAMA Intern Med, 2014, 174(4 ): 564-574.

共引文献451

同被引文献93

引证文献10

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部